$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
舒尼替尼使胃肠道间质瘤患者生存获益
2025-10-19 11:44:20
Check Details
舒尼替尼的服用规格
2025-10-19 11:44:20
Check Details
瑞格非尼治疗胃肠道间质瘤 (GIST) 患者
2025-10-19 11:44:20
Check Details
舒尼替尼获批治疗胃肠道基质肿瘤的患者
2025-10-19 11:44:20
Check Details
瑞格非尼治疗转移性胃肠道间质瘤患者
2025-10-19 11:44:20
Check Details
瑞格非尼治疗晚期胃肠道间质瘤的疗效和安全性:3期试验
2025-10-19 11:44:20
Check Details
索拉非尼治疗胃肠间质瘤
2025-10-19 11:44:20
Check Details
瑞戈非尼延长胃肠道间质瘤患者生存期
2025-10-19 11:44:20
Check Details
瑞格非尼治疗伊马替尼耐药的胃肠道间质瘤患者
2025-10-19 11:44:20
Check Details
舒尼替尼治疗格列卫治疗失败的胃肠间质瘤患者
2025-10-19 11:44:20
Check Details
瑞戈非尼提高胃肠道间质瘤患者的无进展生存期
2025-10-19 11:44:20
Check Details
瑞格非尼降低胃肠道间质瘤患者疾病进展风险
2025-10-19 11:44:20
Check Details
1
2
...
6798
6799
6800
6801
6802
6803
6804
...
10232
10233
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
2
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
3
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
4
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy
5
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
6
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
7
Fezolinetant (Veozah) Dosing and Liver Monitoring Guide
8
Lusutrombopag Safety and Dosing: Thrombosis Risk and Indications
9
Mirogabalin for Neuropathic Pain: Onset Time and Dosing Strategy
10
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
11
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
12
Anagrelide and Myelofibrosis Risk: Controversy and Monitoring in ET Treatment